Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Foresite Capital
BioCentury | Mar 21, 2025
Finance
Maxion, Ampersand, Latigo, Arbor raise private rounds: Finance Report
Plus: SV Health Investors hits $250M goal for second Dementia Discovery Fund
BioCentury | Feb 13, 2025
Finance
Newleos launches with $93.5M, neuropsychiatry candidates from Roche: Venture Report
Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more
BioCentury | Feb 6, 2025
Product Development
AI-based predictive biology coming soon, Foresite’s Bajaj says
CEO of Foresite Labs betting on integrating AI/MI with medical product R&D — The BioCentury Show
BioCentury | Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
BioCentury | Jan 14, 2025
Finance
How VCs at the AI-bio interface set up their portfolios for success
Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem
BioCentury | Jan 10, 2025
Finance
Life science VCs driving AI innovation: the view from the interface in 2025
How VC firms focused on AI-driven drug development think about the resources and strategies needed to turn promise into reality
BioCentury | Dec 13, 2024
Editor's Commentary
VC fundraising in a post-‘supercycle’ era: a Perspective
Some firms are no longer making their latest funds their largest; others may follow
BioCentury | Dec 12, 2024
Management Tracks
Two more C-suite hires at Xaira
Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Oct 18, 2024
Management Tracks
Co-founders Mulvaney, Brennan return to BenevolentAI as CEO Moeller departs
Plus: Sage downsizes and updates from Xaira, DNA Script, Renovaro, Achieve, Adverum and more
Items per page:
1 - 10 of 267